Nxera Pharma Co., Ltd. · TSE:4565
Nxera Pharma — Endpoints News Virtual Event (May 2025)
17 slides from Nxera Pharma's conference presentation, May 23, 2025
Slide 1: Launching a Specialty Medicine in Japan Successfully
EXTERNAL NON-CONFIDENTIAL Launching a Specialty Medicine in Japan Successfully
Slide 2: Disclaimer
Disclaimer The material that follows is a presentation of general background information about Nxera Pharma Co., Ltd and its subsidiaries (collectively, the “Company”) as of the date of this presentation. This material has been prepared solely for informational purposes and is not to be construed as
Slide 3: Company and Speaker Introduction
Company and Speaker Introduction 01
Slide 4: Introduction of speakers
Introduction of speakers Chris Cargill Leads Nxera globally 15 years’ experience in biotech and pharma, President and previously biotech M&A at J.P. Morgan. CEO U.K./Japan based Manages Nxera’s operational functions Toshi Maeda Prior general management, commercial and strategy leadership rol
Slide 5: Building on a 30+ Year Heritage to Create a Fully Integrated Biopharma from Japan
Building on a 30+ Year Heritage to Create a Fully Integrated Biopharma from Japan 1990-2010 2015 2023 2024 Launched a company dedicated Out-licensed programs to global Promoted to PRIME segment of to bringing innovation to Japan pharma to generate profit, cash TSE, improving access to IPO on TSE (
Slide 6: Our Business Model is to Deliver Medical Innovation to Patients in Japan and Globally
Our Business Model is to Deliver Medical Innovation to Patients in Japan and Globally In-house development and commercialization of select wholly owned programs for Japan/APAC Late-stage clinical development and commercialization for in-licensed assets in Japan/APAC Partnering assets with early clin
Slide 7: Market Dynamics and Key Success Factors
Market Dynamics and Key Success Factors 02 7
Slide 8: Market Dynamics for Specialty Business in Japan
Market Dynamics for Specialty Business in Japan Timely reimbursement Universal healthcare End-to-end strategy • Reimbursement (announcement • Japan has universal healthcare • Deep understanding on key of NHI price and listing) takes less system, and all residents (125 stakeholders (i.e., MHLW, PMDA,
Slide 9: Commercialization Key Success Factors for Specialty Product Launches
Commercialization Key Success Factors for Specialty Product Launches Traditional Best practices Functional Develop overarching strategy first alignment Each function operates separately Each function fully understands company-wide Alignment process occurs at the end strategy and who does wha
Slide 10: Nxera Case Study - PIVLAZ
Nxera Case Study - PIVLAZ® 03 10
Slide 11: Our experience bringing PIVLAZ to market for aSAH patients
Case in point – Our experience bringing PIVLAZ® to market for aSAH patients is a model for ‘what good looks like’ for commercial launch excellence Selective endothelin A (ETA) receptor antagonist, medicine for the prevention of cerebral vasospasm PIVLAZ® (CV) after aSAH (aneurysmal subarachnoid hemo
Slide 12: We have rapidly built physicians' confidence on PIVLAZ and it is becoming standard of care
Case in point – We have rapidly built physicians’ confidence on PIVLAZ® and it is quickly becoming the standard of care (SoC) with neurosurgeons Successfully making PIVLAZ® new SoC in Japan Achieved high sales productivity • 100+ Real world data generation and Included in Japan • Tracked top sales f
Slide 13: Nxera Strategy and Key Takeaways
Nxera Strategy and Key Takeaways 04
Slide 14: A lot of opportunities in specialty business in Japan, however hurdles exist for ex-Japan biotechs
A lot of opportunities in specialty business in Japan, however hurdles exist for ex-Japan biotechs Opportunities in specialty business Hurdles of Japanese market • 3rd largest single pharma market • Requires deeper know-how to • Low-hanging fruit disappears so win the market, especially for specialt
Slide 15: A Japan-First, Biotech Mindset makes Nxera Pharma the Partner of Choice for Japan
A Japan-First, Biotech Mindset makes Nxera Pharma the Partner of Choice for Japan Biotech mindset, no hierarchy, rapid-decision-making US/EU biotechs Knowledge and experience working in Japan Japan and APAC Highly innovative Experienced development and regulatory team New medicines assets St
Slide 16: Nxera's aspiration is to become a Next Era Biopharma in Japan
Nxera’s aspiration is to become a Next Era Biopharma in Japan Advance inhouse and partnered programs for global and Japan markets Use strong capital position to in-license innovative Phase 2 / 3 assets from the US and Europe with focus on specialty, rare and orphan drugs Active Business Development
Slide 17: Thank you
Thank you BREAKTHROUGHS IN PROGRESS ● BREAKTHROUGHS IN PROGRESS ● BREAKTHROUGHS IN PROGRESS
Nxera Pharma — Endpoints News Virtual Event (May 2025) on 6ix